Published online Aug 16, 2023. doi: 10.12998/wjcc.v11.i23.5447
Peer-review started: May 24, 2023
First decision: June 12, 2023
Revised: June 15, 2023
Accepted: July 18, 2023
Article in press: July 18, 2023
Published online: August 16, 2023
Processing time: 84 Days and 5.7 Hours
Patients with endometrial cancer have an early onset of clinical symptoms, and although the prognosis for patients with early adjuvant postoperative treatment is generally good, patients who do not receive timely treatment may develop postoperative recurrence or metastasis, which has been associated with a poor prognosis and a high mortality rate, therefore requiring adjuvant postoperative treatment depending on the patient's pathology.
To determine the efficacy and prognosis of adjuvant treatment of endometrial cancer with medroxyprogesterone acetate and medroxyprogesterone acetate and to evaluate their safety.
To provide a reference for the prognosis and anesthesia of clinical operations.
Kaplan-Meier curve analysis and log-rank test were performed to determine the potential influencing factors on the 5-year cumulative survival rate of the study patients, while Cox regression analysis was performed to identify the factors influencing the survival prognosis of endometrial cancer.
The Cox regression analysis revealed that age [hazard ratio (HR) = 4.636, 95% confidence interval (95%CI): 1.411-15.237)], pathological type (HR = 6.943, 95%CI: 2.299-20.977), molecular typing (HR = 5.789, 95%CI: 3.305-10.141), myometrial infiltration (HR = 5.768, 95%CI: 1.898-17.520) were influential factors in the prognosis of patients with early-stage high-risk endometrial cancer.
The possibility of the long-term prognostic benefit of adjuvant postoperative radiotherapy in patients with early-stage high-risk endometrium is worthy of clinical consideration.
Future research may investigate optimal medroxyprogesterone acetate dosage and duration for early endometrial cancer. Can explore combining medroxyprogesterone acetate with other therapies. Also, include patient-reported outcomes to understand treatment impact.